In This Section

Home / Blurb / Discussion List

FDA Approves Ibrutinib Plus Obinutuzumab for CLL/SLL

Jan 28, 2019, 10:07 AM
On January 28, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica, Janssen and Pharmacyclics) in combination with obinutuzumab for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Read the Janssen press release here.

 Posted January 28, 2019

Leave a comment